
Nanoscope Technologies LLC Profile last edited on: 11/12/2019
CAGE: 5KA02
UEI: H6DNZXT5MMT1
Business Identifier: Technologies used by pathologists to diagnose diseases Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 24
County: Tarrant
Congr. District: 24
County: Tarrant
Public Profile
Organized around development of new methods and devices for scientific, industrial and biomedical applications, Nanoscope has developed a range of biomedical technologies which include diagnostics and therapeutic devices and molecules. The firm has also developed various biomedical technologies to include diagnostics and therapeutic devices and molecules. With capabilities in microscopic imaging and spectroscopy based pathological analysis of cancer and diseases with non-neoplastic changes. Early detection of diseases (via rigorous analysis) can greatly increase the chances for successful and recurrence-free treatment. NanoScope Technologies has developed multimodal pathological microscope that enables simultaneous characterization of nano-architecture of selected cells while visualizing and imaging of morphological features by pathologists. This economical and fully automated system will aid label-free detection of early neoplastic as well as non-neoplastic changes that occur in various human and animal diseases. The firm is working on Multi-Characteristic Opsin for efficient light activation. Optogenetics has revolutionized basic biomedical research and is expected to have therapeutic impact in near future. Current electrode based stimulation methods are invasive, non-specific, and have limited resolution. NanoScope Technologies has developed a suite of synthetic Multi-Characteristics Opsins having high light sensitivity for sensitizing variety of cells/tissues towards light so that the targeted cells can be optically activated using very low intense light. Besides basic research, the therapeutic potential includes vision restoration and other physiological disorders. Also working on NanoSpectro device for painless in-situ cancer diagnosiss, NanoScope Technologies has developed novel, non-invasive patent pending Cancer Diagnostic Device as a low powered, safe bright light device that can detect and differentiate cancer tissue from normal tissue and benign tumor.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
15-19Revenue Range
1.5M-2MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2023 | 2 | NIH | $1,592,229 | |
Project Title: Mechanosensitive Channel based Pressure-Modulating Gene Therapy for Glaucoma Treatment | ||||
2022 | 2 | NIH | $2,114,715 | |
Project Title: Targeted Nano-Enhanced Optical Delivery of Opsin for Dry-AMD Therapy | ||||
2022 | 2 | NIH | $3,915,599 | |
Project Title: Ambient Light Activatable Opsin Based Therapy for Age-Related Macular Degeneration | ||||
2016 | 1 | NIH | $224,370 | |
Project Title: Targeted Nano-enhanced Optical Delivery of OPSIN for dry-AMD therapy |
Key People / Management
Sulagna Bhattacharya -- CEO and COO
Beamon Agarwal -- Clinical Coordinator
Adnan Dibas
Samarendra Mohanty -- Founder and Chief Scientific/Technology Officer
Sanjay Pradhan -- Senior Scientist
Hrebesh M Subhash -- Senior Technology Officer
Weldon Wright -- CMO
Beamon Agarwal -- Clinical Coordinator
Adnan Dibas
Samarendra Mohanty -- Founder and Chief Scientific/Technology Officer
Sanjay Pradhan -- Senior Scientist
Hrebesh M Subhash -- Senior Technology Officer
Weldon Wright -- CMO
Company News
There are no news available.